SNN

Healthcare Medical Devices

Smith & Nephew plc

$26.87
-0.05 -0.19% today

Price History

Not enough data

Key Stats

Market Cap
11.25B
Avg Volume
1.64M
P/E (TTM)
18.28
EPS
$1.47
52W High
$37.51
52W Low
$26.12
Div. Yield
1.5%

Analyst Ratings

Hold
1
Str Buy
0
Buy
5
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
11.15
P/B Ratio
11.04
P/S Ratio
1.79
EV/EBITDA
43.64
EV/Revenue
9.57
PEG Ratio
1.01

Margins

Gross Margin 68.4%
Operating Margin 14.5%
Net Margin 10.1%
EBITDA Margin 21.9%

Growth & Returns

Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
5.7%
Earnings Growth (QoQ)
3.4%
Return on Equity
11.9%
Return on Assets
5.2%

Liquidity & Leverage

Current Ratio
2.14
Quick Ratio
1.11
Debt / Equity
0.73
Total Cash
754.00M
Total Debt
3.78B

About

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

www.smith-nephew.com